GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWTUY) » Definitions » Equity-to-Asset

Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Equity-to-Asset : 0.48 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Swedish Orphan Biovitrum AB Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Swedish Orphan Biovitrum AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $3,447 Mil. Swedish Orphan Biovitrum AB's Total Assets for the quarter that ended in Mar. 2024 was $7,157 Mil. Therefore, Swedish Orphan Biovitrum AB's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.48.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Equity-to-Asset or its related term are showing as below:

SWTUY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37   Med: 0.51   Max: 0.72
Current: 0.48

During the past 13 years, the highest Equity to Asset Ratio of Swedish Orphan Biovitrum AB was 0.72. The lowest was 0.37. And the median was 0.51.

SWTUY's Equity-to-Asset is ranked worse than
62.74% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs SWTUY: 0.48

Swedish Orphan Biovitrum AB Equity-to-Asset Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Equity-to-Asset Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.42 0.48 0.51 0.46

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.37 0.46 0.46 0.48

Competitive Comparison of Swedish Orphan Biovitrum AB's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Equity-to-Asset falls into.



Swedish Orphan Biovitrum AB Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Swedish Orphan Biovitrum AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=3301.65/7216.795
=0.46

Swedish Orphan Biovitrum AB's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=3446.928/7157.416
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Swedish Orphan Biovitrum AB  (OTCPK:SWTUY) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Swedish Orphan Biovitrum AB Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description

Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).